If you have been reading about BPC-157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-08. Numbers and descriptions here follow the published literature rather than marketing material.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
While the +4 and the −3 positions in the Kozak sequence have the greatest relative importance in the establishing a favorable initiation context a CC or AA motif at −2 and −1 were found to be important in the initiation of translation in tobacco and maize plants. Protein synthesis in yeast was found to be highly affected by composition of the Kozak sequence in yeast, with adenine enrichment resulting in higher levels of gene expression. A suboptimal Kozak sequence can allow for the pre-initiation complex (PIC) to scan past the first AUG site and start initiation at a downstream AUG codon.
== Dietary purpose == Protein bars are targeted to people who primarily want a convenient source of protein that does not require preparation (unless homemade). There are different kinds of food bars to fill different purposes. Energy bars provide the majority of their food energy (calories) in carbohydrate form. Meal replacement bars are intended to replace the variety of nutrients in a meal. Protein bars are usually lower in carbohydrates than energy bars, lower in vitamins and dietary minerals than meal replacement bars, and significantly higher in protein than either. Protein bars may contain high levels of sugar and sometimes are called "candy bars in disguise". Alternative protein bars may use insect protein as an ingredient. Vegan protein bars contain only plant-based proteins from sources like peas, brown rice, hemp, and soybeans. Protein bars are mainly marketed to athletes or exercise enthusiasts for muscle building or as a wellness-themed convenience food. The global market is growing and expected to reach US$2 billion in annual sales in 2026. There is a disagreement over the amount of protein required for active individuals and athletic performance. Some research shows that protein supplementation is not necessary. Athletes generally consume higher levels of protein as compared to the general population for muscular hypertrophy and to reduce lean body mass lost during weight loss. Specialists have stated that the general American population is not lacking in protein.
== Early life == Emma Willis was born in Sutton Coldfield, Birmingham, attending Wylde Green Primary School and then John Willmott School in Sutton Coldfield. She began modelling at the age of 15, and during her career worked for a range of magazines, retailers and companies including Marie Claire, Elle, Vogue, GAP and Chanel.
The addition of mirtazapine to a monoamine oxidase inhibitor, while potentially having typical or idiosyncratic (unique to the individual) reactions not herein described, does not appear to cause serotonin syndrome. This is per the fact that the 5-HT2A receptor is the predominant serotonin receptor thought to be involved in the pathophysiology of serotonin syndrome (with the 5-HT1A receptor seeming to be protective). Mirtazapine is a potent 5-HT2A receptor antagonist, and cyproheptadine, a medication that shares this property, mediates recovery from serotonin syndrome and is an antidote against it. There is a possible interaction that results in a hypertensive crisis when mirtazapine is given to a patient who has already been on steady doses of clonidine. This involves a subtle consideration, when patients have been on chronic therapy with clonidine and suddenly stop the dosing, a rapid hypertensive rebound sometimes (20%) occurs from increased sympathetic outflow. Clonidine's blood pressure lowering effects are due to stimulation of presynaptic α2 autoreceptors in the CNS which suppress sympathetic outflow. Mirtazapine itself blocks these same α2 autoreceptors, so the effect of adding mirtazapine to a patient stabilized on clonidine may precipitate withdrawal symptoms. Mirtazapine has been used as a hallucinogen antidote to block the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).
Sources: en.wikipedia.org
The first fully virtual court hearing of a capital case was made via Zoom on 23 April 2020, when the Court of Appeal acquitted 27-year-old Singaporean drug suspect Mohammad Azli Mohammad Salleh and dismissed both his drug charge and his death sentence. There were originally two executions scheduled for drug traffickers Syed Suhail bin Syed Zin and Mohd Fadzir bin Mustaffa on 18 September 2020 and 24 September 2020 respectively, but they were subsequently postponed due to stays of execution granted pending last-minute appeals against the death sentences. As a result, there was no one executed in 2020. Similarly between January and October 2021, no new execution dates were set for the inmates on Singapore's death row, due to the ongoing COVID-19 pandemic and resurgence of community cases. The execution of Nagaenthran K. Dharmalingam was supposed to be carried out on 10 November 2021, but it was postponed due to Nagaenthran contracting COVID-19. The suspension of Nagaenthran's execution in 2021 also led to no executions being carried out in 2021 itself. There were originally two executions of Roslan Bakar and Pausi Jefridin to be carried out on 16 February 2022 and a third execution of Rosman Abdullah on 23 February 2022 before they were postponed due to the men's appeals. Due to the increasing notices of executions being revealed publicly, there were lingering concerns from civil groups and international figures that Singapore might resume executions to accommodate the growing death row inmate population at Changi Prison.
This abnormal chromosome was dubbed the Philadelphia chromosome - as both scientists were doing their research in Philadelphia, Pennsylvania. Thirteen years later, with the development of more advanced techniques, the abnormal chromosome was shown by Janet Rowley to be the result of a translocation of chromosomes 9 and 22. Identification of the Philadelphia chromosome by cytogenetics is diagnostic for CML. More than 780 leukemias and hundreds of solid tumors (lung, prostate, kidney, etc.) are now characterized by an acquired chromosomal abnormality, whose prognostic value is crucial. The identification of these chromosomal abnormalities has led to the discovery of a very large number of "cancer genes" (or oncogenes). The increasing knowledge of these cancer genes now allows the development of targeted therapies, which transforms the prospects of patient survival. Thus, cytogenetics has had and continues to have an essential role in the progress of cancer understanding. Large databases (Atlas of Genetics and Cytogenetics in Oncology and Haematology, COSMIC cancer database, Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer) allow researchers and clinicians to have the necessary corpus for their work in this field.
=== RNaseA === In 1959, Fred Richards discovered that a proteolytic enzyme, Subtilisin, had the ability to cleave the enzyme Ribonuclease A into two components, a peptide corresponding to the first 20 amino acids of the enzyme (S-Peptide) and the remainder of the protein (S-Protein). When separated from one another, each piece was inactive but when they were simply mixed together, full enzymatic activity was restored. Hofmann speculated that this system might be a model for the way peptide hormones interact with their receptors. Structure-function studies with ACTH were complicated by the necessity to assess activity in the whole animal. The S-Peptide:S-Protein system afforded a simple system with none of the biological complications inherent in testing ACTH analogs. To study which amino acids might be important in establishing the binding between peptide hormones and their receptors, Hofmann and his group began a systematic evaluation of the contributions each amino acid in the S-Peptide molecule made to the binding with S-Protein. The ability of synthetic analogs of S-Peptide to activate S-Protein correlated well with those of synthetic ACTH analogs to elicit hormonal activity: 1) only a portion of the S-Peptide chain was essential for re-establishing full activity with the S-Protein; 2) methionine was not important; 3) substituting one particular amino acid in the peptide not only destroyed the activity of the peptide but created an antagonist as well.
Sources: en.wikipedia.org
Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. Imetelstat is an oligonucleotide telomerase inhibitor. By blocking telomerase activity, imetelstat causes telomere shortening, inhibits the proliferation of malignant stem and progenitor cells and induces cell death, ultimately leading to a reduction in malignant clones. The most common adverse reactions include decreased platelets, decreased white blood cells, decreased neutrophils, increased aspartate aminotransferase, increased alkaline phosphatase, increased alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache. Imetelstat was approved for medical use in the United States in June 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
But the most absurd of all, and also the most important, is that in his last recital, Sucre says that he convenes the assembly, because he has that right as "the majority of the liberation army is made up of Colombians." This would indicate the total lack of respect that Sucre had, both for the Peruvian government and for Peruvians. In addition, Sucre would have no authority to call an assembly (neither by Bolívar nor by the Congress of Peru), and yet he called it. Later Simón Bolívar would annul the right to veto that he had granted to the Peruvian congress to endorse the acts of the assembly of 1825. It should also be added that, in the Independence of Upper Peru, the indigenous masses did not participate, only the upper strata of the population, that is, Criollos of the elite. However, due to his control of the army and the congresses of Lima and Chuquisaca, Sucre and especially Bolívar held the last word on the destiny of Upper Peru. Limeños were annoyed that according to the principle of Uti possidetis iuris, the viceroyalty of New Granada had become independent intact, while theirs had not. Later he would come to offer the territories of the then southern coast of Peru (Tacna, Arica and Tarapaca) to Bolivia, but these procedures would be prevented by the fall of the Bolívar and Sucre dictatorship in Peru and Bolivia. Furthermore, in a letter to the Peruvian Foreign Ministry, Ortiz de Zevallos revealed Sucre's decisive opposition to Bolívar's Federation project until Peru was divided into two States.
=== Mimicry === Much like the Salticidae family of spiders, P. phalangioides also use mimicry as a predatory tactic to subdue their prey; however, unlike jumping spiders, P. phalangioides do not rely on vision for predation. This mimicry consists of creating specialized vibrations to trick the prey into thinking that it has caught an insect or another spider. The prey then slowly approaches its supposed catch at which point the P. phalangioides spider raises up on its long legs. The spider patiently waits until the exact moment at which the prey touches one of its legs. Then, the P. phalangioides spider quickly immobilizes its prey by using its legs to wrap it up in layers of silk. Its long legs give it plenty of distance from the prey to avoid being bitten in retaliation. After immobilizing its prey, P. phalangioides can administer their venomous bite to the prey and consume it. Even forms of prey that do not fully make it onto the web of P. phalangioides are not safe. Often, prey will trip over the edges of the web, thus providing P. phalangioides with an optimal time to attack. P. phalangioides is capable of clinging onto their web with two of their legs while the rest of their body leans out of the web and shoots silk in the direction of the prey to subdue it.
Thus, the two substrates of this enzyme are D-galactose (shown in its aldehydo form) and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are D-galactono-1,5-lactone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-galactose:NADP+ 1-oxidoreductase. Other names in common use include D-galactose dehydrogenase (NADP+), and galactose 1-dehydrogenase (NADP+). This enzyme participates in galactose metabolism.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.